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Alzheimer’s Disease (AD) is the most frequent cause of dementia in the elderly. Prevalence 
is about 10% in populations of 65 years and older and it increases rapidly as life expectancy 
increases. Estimates indicate that there are around 36 million cases around the world, while 
associated costs are higher than US$ 600 billion (Wimo & Prince, 2010). The 
histopathological characteristics of AD are represented by two main lesions: senile plaques 
and neurofibrillary tangles (NFTs). The formers main component is the amyloid beta 
peptide (Aǃ peptide) adopting ǃ-sheet structures, while the latter have the 
hyperphosphorylated tau protein and pathological forms of tau as a major component 
(Maccioni et al., 2001). AD has triggered a plethora of hypotheses to explain its 
pathogenesis, possibly strengthened by the fact that no cure has yet been found for this 
devastating disease since its first description by Alois Alzheimer in 1907. Although, 
significant advances have been made in neuroscience in the last few decades, the data has 
not provided effective therapeutic solutions for AD.  
1.1 Many hypotheses, one disease, no cure 
Many hypotheses have been postulated on the physiopathology of AD (Maccioni and Perry, 
2009). During the last two decades, the central paradigm was the amyloid hypothesis, based 
on events triggered by the A cascade: as the unique driving force in neurodegeneration. 
The hypothesis proposes that accumulation of Aǃ in the brain primarily influences 
pathogenesis of the disease and the rest of the processes in AD  are results of the imbalance 
between production and degradation of Aǃ (Hardy & Selkoe, 2002). Nevertheless, recent 
clinical trials based on this hypothesis have been inconclusive. In fact, the amyloid cascade 
hypothesis has resulted in misleading approaches to find therapeutic alternatives until 




When Things Go Wrong – Diseases and Disorders of the Human Brain 
 
126 
recently (Hardy, 2009). These targets include A vaccines, antibodies against -amyloid, -
secretase inhibitors and drugs that block direct A aggregation (Extance, 2010; Gandy, 2010; 
Rinne et al., 2010). 
In this context, new paradigms have been proposed that consider all the  implications of the 
disease and valid therapeutic targets are now emerging. AD is a complex illness involving 
many risk factors. In fact, during its progress, oxidative stress as well as innate immune 
system activation appears to play a role. Considering AD as a result of multifactorial events, 
it is plausible that a concatenated series of damage signals affect brain cells, mainly 
microglial cells, thus triggering an abnormal response in neuro-immunomodulation with 
consequent effects on neurons. A common molecular feature of these anomalous signals 
leads to tau self-aggregation into oligomers as a final event (Maccioni et al., 2010). 
1.2 The neuroimmunomodulation hypothesis of AD 
During the past few years, increasing sets of evidence support the major role of deregulation 
of interaction patterns between glial cells and neurons in the pathway toward neuronal 
degeneration. Neurons and glial cells, together with brain vessels, constitute an integrated 
system for brain function. Inflammation is a process intimately related to the onset of 
several neurodegenerative disorders, including Alzheimer's disease (AD). Several 
hypotheses have been postulated to explain the pathogenesis of AD, but none provide 
insight into the early events that trigger metabolic and cellular alterations in neuronal 
degeneration (Rojo et al., 2008).  
A study of the factors resulting in AD, has led us to postulate the neuroimmunomodulation 
hypothesis, which focus on pathological events in the neuron-glia cross-talks. Data suggests 
an important role of the immune system in regulating the progression of the brain aging and 
neurodegenerative diseases, where the crosstalk between these systems determines the 
progression of pathological event (Lucin & Wyss-Coray, 2009). In this context, the microglia, 
the resident macrophages of the CNS, are key factors in the regulation of local cellular 
environment  relative to inflammation. The persistence of activated microglia long after acute 
injury and in chronic disease suggests that these cells have an innate immune memory of 
tissue injury and degeneration. Microglial phenotype is also modified by systemic infections or 
inflammation. Systemic inflammation is associated with a decline in function in patients with 
chronic neurodegenerative disease, both acutely and in the long term (Perry et al., 2010).  
The idea that alterations in the brain immunomodulation are critical for AD pathogenesis 
provides the most integrative view on this cognitive disorder, considering that converging 
research lines have revealed the involvement of inflammatory processes in AD. Studies on 
microglia and neuronal cultures, together with experiments in animal models, and the 
clinical evidence, suggest that a series of endogenous damaged signals that include, among 
other factors, A oligomers, oxygen free radicals, iron overload, cholesterol levels in 
neuronal rafts, folate deficiency, head injury, LDL species and homocysteine trigger the 
activation of microglial cells. Inflammatory cytokines play a dual role: either promoting 
neurodegeneration or neuroprotection. This equilibrium is shifted toward the 
neurodegenerative phenotype upon the action of several risk factors that trigger innate 
damage signals  and activate microglia and then release of inflammatory cytokines (Figure 1) 
(Fernandez et al., 2008; Maccioni et al., 2009).  
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Fig. 1. Neuroinmmunomodulation Hypothesis in the pathogenesis of AD. Schematic 
representation of the hypothetical roles of endogenous danger/alarms signals built into the 
innate immune system in the early stages of the pathogenesis of AD. Consequentially, (as it 
may apply to different individuals), danger signals can trigger innate immune system alarm 
mechanisms resulting in the production of tumor necrosis factor alpha (TNF-┙), interleukin-1┚ 
IL-1┚) and interleukin-6 (IL-6). These signals would then mediate neuronal damage, reflected 
in alterations such as tau hyperphosphorylation and paired helical filaments formation. 
The progression of AD, encompasses increased damage in brain parenchyma preceding the 
onset of symptoms. Suggesting that tissue distress trigers damage signals and drives 
neuroinflammation. These signals via toll-like receptors, or receptors for highly glycosylated 
end products, or other glial receptors activate sensors of the native immune system, 
inducing the anomalous release of cytokines and promoting the neurodegenerative cascade, 
a hallmark of brain damage that correlates with cognitive decline. We show that this 
activation induces NFĸ-ǃ expression with the consequent release of cytokine mediators such 
as TNF-ǂ, IL-6 and IL-1ǃ. An over expression of these mediators may trigger signaling 
cascades in neurons leading to activation of protein GSK3ǃ, cdk5 kinases, along with 
inhibition of phosphatases such as PP1, resulting in hyperphosphorylation and self-
aggregation of tau protein into neurotoxic oligomeric species. The aggregation of tau protein 
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is the final pathway and key event in the Alzheimer´s pathogenesis (Morales et al., 2010, 
Farias et al., 2011). 
The evidence correlating inflammation and tau phosphorylation has been provided by 
neuropathology markers and mouse transgenic models with Alzheimer disease. Activated 
microglia has been found in the postmortem brain tissues of various human tauopathies 
including Alzheimer’s disease (AD) and frontotemporal dementia (FTD) (Gebicke-Haerter, 
2001). The administration of LPS, in order to generate systemic inflammation, significantly 
induced tau hyperphosporylation in the triple transgenic mouse model of AD (3xTg) and 
rTg4510 mice. In line with this evidence, microglial activation also preceded tangle 
formation in a murine model of tau pathology (Yoshiyama et al., 2007). Also 
immunosuppression of young P301S Tg mice with FK506 attenuated tau pathology and 
increased lifespan, thereby linking neuroinflammation to early progression of tauopathies 
(Yoshiyama et al., 2007, Lee et al., 2010; Kitazawa et al., 2005). In addition, the 
neurodegenerative lesions caused by human truncated tau promote inflammatory response 
manifested by upregulation of immune-molecules (CD11a,b, CD18, CD4, CD45 and CD68) , 
the morphological activation of microglial cells and leukocyte infiltration in a rat model of 
tauopathy (Zilka et al., 2009).  
On the other hand, it has been demonstrated that proinflammatory cytokines, such as 
interleukin-1 (IL-1), interleukin-6, and nitric oxide, released from astrocytes can accelerate 
tau phosphorylation and formation of neurofibrillary tangles (NFTs) in vitro (Li et al., 2003, 
Quintanilla et al., 2004, Saez et al., 2004). Likewise, the activation of microglia and the 
microglial-derived proinflammatory cytokine TNF can induce accumulation of 
aggregation-prone tau molecules in neurites via reactive oxygen species (Gorlovoy et al., 
2009). Recently, it has been identified the fractalkine receptor (CX3CR1) as a key microglial 
pathway in protecting against AD-related cognitive deficits that are associated with aberrant 
microglial activation and elevated inflammatory cytokines. In vitro experiments 
demonstrated that microglial activation elevates the level of active p38 MAPK and enhances 
tau hyperphosphorylation within neurons which can be blocked by administration of an 
interleukin-1 receptor antagonist and a specific p38 MAPK inhibitor. This finding suggests 
that CX3CR1 and IL-1/p38 MAPK pathway may serve as novel therapeutic target for 
human tauopathies (Bhaskar et al., 2010, Cho et al., 2011).  
Other sources of evidence to support neuroimmunomodulation theory are epidemiological 
data that show individuals consuming nonsteroidal anti-inflammatory drugs (NSAIDs) 
have a lower risk of AD (McGeer et al, 2006). In fact, patients receiving systemic NSAIDs 
developed significantly less AD manifestations, suggesting that ameliorating inflammation 
in the brain helps to prevent or slow down the onset of AD (McGeer et al., 1996). However, 
controlled randomized clinical trials with common NSAIDs have not shown a positive effect 
in the decline of AD (Rojo et al, 2008).  
Genetic and epidemiological evidence has implicated increased TNF production as a risk 
factor for AD. In fact, excess TNF is present in the CSF of individuals with Alzheimer's disease 
(AD). Recently, Tobinick and colleagues have demonstrated that perispinal administration of 
etanercept, a potent anti-TNF fusion protein, produced sustained clinical improvement in a 6-
month, open-label pilot study in patients with AD ranging from mild to severe. Subsequent 
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case studies have documented rapid clinical improvement following perispinal etanercept in 
both AD and primary progressive aphasia, providing evidence of rapidly reversible, TNF-
dependent, pathophysiological mechanisms in AD and related disorders. Although, some 
researchers undermine results by their methodologies, perispinal etanercept for AD needs 
further studies to be validated and gives us new perspectives to support the critical role of 
immune system in AD (Tobinick & Gross, 2008a, 2008b; Tobinick, 2009).  
1.3 Integrated efforts toward prevention, diagnosis and treatment of AD 
In the field of prevention of AD, studies have indicated that dietary factors, antioxidants, 
exercise along with healthy styles of life contribute to diminish risk factors for AD. In 
addition, the search for dietary supplements, phytocomplexes, and nutraceuticals  from 
natural sources have suggested novel preventive alternatives against AD, based on 
preclinical and clinical trials outcomes. These include molecular complexes with either anti-
inflammatory, antioxidant or antiamyloidogenic properties. The extraordinary properties of 
polyphenolic extracts may help as coadjuvant in the AD therapy. Investigations are directed 
to design powerful nutraceuticals, which derive from distinct sources and could be 
consumed by the high-risk population. This provides data on the action of Shilajit and other 
nutraceuticals as a new tools for prevention.  
Innovative approaches are critical in order to improve early detection of AD, which in turn 
is critical to find therapeutic solutions, and for monitoring new drugs developments against 
the disease. Our laboratory has developed an integrated strategy to establish reliable 
diagnosis tools with a high efficacy. We found that different benzimidazoles that tag 
aggregates of tau protein, serve as specific markers for PET neuroimaging, in order to 
monitor advances of the disease. Clinical studies are underway to validate PET images that 
differentiate stages of AD and controls. As a complementary approach, we have studied tau 
in cerebrospinal fluid (CSF) and also in peripheral blood platelets, providing promising 
biological non-invasive markers for AD (Maccioni et al, 2006; Neumann et al, 2011).  
Until now there are no drugs available as an efficient therapy of AD. Current therapeutic 
targets focus on avoiding formation of tau aggregates in neurons, modulation of the innate 
immune system, chelating heavy metals and diminishing the burden of the amyloidogenic 
molecular variants. On one hand, clinical trials include: tau aggregation inhibitors (like 
methylene blue with promising results in phase II trials), tau kinase inhibitors, microtubule 
stabilizers and unfolded protein respond modulators. As mentioned earlier, it has been 
demonstrated that the relationship between anti-inflammatory molecules (NSAIDs) and the 
prevalence of AD in longitudinal studies. Unfortunately, no specific drug has a positive 
effect in the treatment of the disease in controlled double-blind trials. It could be 
hypothesized that we still do not understand enough about the specific molecules and its 
receptors involved in the immune system’s cross-talk between neuron and glial cells. We 
believe that the next generation of drugs should focus on these specific targets.  
2. New tools for AD diagnosis 
More than a century has passed since Dr. Alois Alzheimer described the case of Auguste D, 
a 51 years old patient with a history of progressive cognitive impairment. Histopathology of 
brain tissue demonstrated the presence of senile plaques, neurofibrillary tangles (NFTs) and 
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arteriosclerotic changes (Alzheimer, 1907). Today, despite the importance of AD (the 
world´s primary cause of neurodegenerative dementia) the advances in knowledge of 
clinical and pathophysiological aspects, and the definitive diagnosis of AD still depends 
mainly on histopathological analysis. 
In contrast, the reliability of standard clinical evaluation is limited, and in most cases allow 
us only to diagnose the disease as "possible" or “probable” AD  (McKhann et al., 1984). This 
shortcoming of standard clinical methods is specially relevant in early and unusual 
presentations of AD and has driven the interest to develop both biochemical and imaging 
tests to support the diagnosis (Dubois et al., 2007; Wiltfang et al., 2007). In this regard the 
2011 diagnostic criteria (McKhann et al., 2011) considered the contribution of markers for 
the pathophysiological process of AD. These criteria divided biomarkers of AD in two 
classes: a) Biomarkers of brain Aǃ deposition –i.e. CSF Aǃ 1-42 levels and brain Positron 
Emission Tomography (PET) amyloid imaging - and b) biomarkers of downstream neuronal 
degeneration or injury –i.e. CSF total and phosphorylated forms of tau; 18 
fluorodeoxyglucose (FDG) PET imaging of temporo – parietal cortex; and atrophy on 
Nuclear Magnetic Resonance (NMR) imaging in medial, basal, and lateral temporal lobe, 
and medial parietal cortex. The contribution of AD biomarkers has made possible to raise 
the concept of preclinical AD as a diagnostic category based on AD biomarkers 
modifications without definite cognitive decline  (Sperling et al., 2011). 
2.1 Role of biomarkers in AD 
A biomarker corresponds to an indicator of the presence or extent of disease, which is 
directly associated with the clinical features and prognosis of the disease. Biomarkers for 
cognitive impairment and dementia have been proposed by several research groups in 
recent years  (Maccioni et al., 2004). The consensus report of "The Ronald and Nancy Reagan 
Research Institute of the Alzheimer's Association" and the "National Institute on Aging 
working group" on “Molecular and Biochemical Markers of Alzheimer’s Disease” (The 
Ronald and Nancy Reagan Research Institute of the Alzheimer’s and Association National 
Institute on Aging Working Group, 1998) listed the specific criteria and features for an ideal 
biomarker of AD. It “should detect a fundamental feature of neuropathology and be 
validated in neuropathologically-confirmed cases: it should have a sensitivity >80% for 
detecting AD and a specificity of >80% for distinguishing other dementias: it should be 
reliable, reproducible non-invasive, simple to perform, and inexpensive”. Based on these 
criteria, scientists have been able to discard many substances that are unsuitable as 
biomarkers and do not contribute or improve AD diagnosis (Mulder et al., 2000). 
Biochemical markers for AD have been extensively sought in bodily fluids, and key proteins 
of AD neuropathology -Aǃ, tau and hyperphosphorylated tau isoforms- have been 
evaluated  as potential markers for AD diagnosis and for follow up in clinical trials. 
2.1.1 Biomarkers in CSF 
As CSF is in close contact with nerve tissue, it is not  surprising that CSF has been 
considered a reliable indicator of brain tissue environment. Most published literature 
described two main types of CSF-based biomarkers : 
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 Amyloid beta (Aβ) levels:  in AD CSF the concentration of Aǃ, fraction 1-42 (Aǃ 1-42) is 
regularly reduced to less than 50% of its normal value and has been considered a 
reliable marker of AD, with a sensitivity of 78% and 81-83% specificity  (Wiltfang et al., 
2007). Low levels of Aǃ 1-42 can also predict the onset of cognitive decline in older 
women without dementia  (Gustafson et al., 2007). Meanwhile, since the fraction Aǃ 1-
40 is the major constituent of total CSF Aǃ, Aǃ 1-42 / Aǃ 1-40 ratio has also been 
evaluated and has been proposed as a better marker than isolated Aǃ 1-42 levels  
(Wiltfang et al., 2007). 
 Tau and phosphorylated tau: Tau protein is aggregated in paired helicoidal filaments 
(PHFs) and neurofibrillary tangles (NFTs) of AD brains and has been proposed as a 
pathogenic protein in the disease (Maccioni, 2011). Tau levels are also increased in CSF 
of AD patients, so they have been studied as suitable biomarkers. In patients with mild 
cognitive impairment -that in many cases will progress to dementia- CSF tau levels can 
differentiate those that correspond to depressive syndromes from those that will 
effectively progress to AD  (Schönknecht et al., 2007). 
Under pathogenic conditions tau undergoes several modifications that include 
phosphorylation, truncation, glycation, etc. (Farías et al., 2011), so these forms of modified 
tau have also been evaluated as biological markers. Tau phosphorylated at threonine 181 (p-
tau 181) demonstrates to be useful for differentiating control and AD subjects from subjects 
with dementia with Lewy Bodies, being a better marker of AD that Aǃ 1-42 and total tau  
(Vanderstichele et al., 2006). Hyperphosphorylated tau increases in AD subjects, as well as 
in those with mild cognitive impairment that will progress to AD  (Andersson et al., 2007; 
Maccioni et al., 2006). 
Aǃ 1-42, total tau and p-tau may serve as useful markers to predict progression from mild 
cognitive impairment to AD (Diniz et al., 2008). CSF p-tau levels also may have a role 
monitoring response to treatment  (Degerman et al., 2007) However, the real value of CSF 
markers to predict progression of cognitive decline is disputed and may be less robust than 
cognitive assessment to predict conversion from mild cognitive impairment to AD  (Gomar 
et al., 2011). Apolipoprotein E (Apo E) ε4 genotype may be related to levels of biomarkers in 
CSF, since increased levels of total tau and p-tau and decreased Aǃ 1-42 have been described 
in CSF of patients with severe involvement of episodic memory and Apo E-ε4 (+)  
(Andersson et al., 2007). 
Although Aǃ and tau levels in CSF are the most studied and validated biological markers of 
AD with enough stability,  (Slats et al., 2011); the mayor pitfall of CSF biological markers is 
the necessity of invasive techniques such as lumbar puncture to obtain samples. Adverse 
effects are present at 11.7% of subjects, being with clinically significant at 3.97%, including 
post lumbar puncture headache 0.98% - 5%  (Maccioni et al., 2006; Peskind et al., 2005). As a 
way to face problems of CSF analyses, new and non-invasive biomarkers available in blood, 
saliva and urine are currently under investigation. 
2.1.2 Peripheral biomarkers 
Levels of Aǃ have been studied in plasma of AD patients. However, Aǃ 1-40 levels are not 
specific for AD and in fact are affected by age (Luchsinger et al., 2007). On the other hand, 
plasma Aǃ 1-42 may be altered early in the disease, but since this marker is not reliable 
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enough, correlation with neuroimages or other biological markers is needed (Blasko et al. 
2008). Other metabolic and nutritional markers have also been studied, including levels of 
folic acid and vitamin B12 but results are conflicting so far  (Irizarry et al. 2005; Isobe et al. 
2005; Köseoglu & Karaman 2007; Serot et al. 2005; Seshadri et al. 2002). 
2.1.3 Apo E polymorphisms 
Apo E is a plasma protein involved in cholesterol transport. In the CNS, Apo E is also 
involved in growth and repair of the nervous system during development and after injury. 
The Apo E gene has 3 alleles: ε2, ε3, ε4. The ε4 allele is associated with an increased risk of 
AD  (Rojo et al., 2006), ε4 allele is present among 40 to 50% AD subjects  (Farrer et al.,1997). 
Actually Apo E- ε4 is considered as a risk factor of AD  (Mayeux et al., 1998).  
2.1.4 Inflammatory markers 
Proinflammatory molecules have been studied as potential peripheral markers of AD. As 
stated in preceding paragraphs, in the context of neuroimmunomodulation hypothesis, 
there is consistent evidence that inflammatory mechanisms play an important role in AD 
pathophysiology. However, results are inconsistent. In patients with AD elevated levels of 
plasma soluble CD-40 and a decrease in TGF-ǃ1 have been described, while assessments of 
IL-1, IL-2, IL-6 and TNF-ǂ have yielded conflicting results  (Rojo et al, 2008). 
2.1.5 Altered p53 
Alterations in the tertiary folding of p53 protein can be recognized in fibroblasts from 
patients with AD (Uberti et al., 2006). This altered protein is also present in blood 
mononuclear cells of AD patients. Measurements of these p53 variants by cytofluorometry 
and immunoprecipitation techniques may serve as AD biomarker with high sensitivity and 
specificity (90% and 77% respectively)  (Lanni et al, 2008; Uberti et al., 2008). 
2.1.6 Platelets Amyloid Precursor Peptide (APP) 
APP is a transmembrane protein that, by proteolytic cleavage, generates Aǃ, the major 
component of senile plaques. Therefore, APP could be a useful biomarker in AD. Platelets 
carry more than 95% of circulating APP, containing all the necessary machinery for APP 
metabolism, so there has been postulated that changes in platelets metabolism that include, 
but are not limited to APP processing, may correlate to brain pathophysiological processes 
of AD  (Hochstrasser et al., 2011; Neumann et al., 2011;  Zainaghi et al., 2007). 
Several APP fractions can be resolved by electrophoresis and immunoblot techniques of 
platelets extracts. Analyses have found a reduction in 130 kDa APP isoforms in relation to 110 
kDa APP in AD patients. These alterations in platelets APP ratio are related to severity and 
progression of the disease  (Borroni et al., 2006) High sensitivity and specificity -around 80 to 
95%- have been described for this technique  (Borroni et al., 2006; Padovani et al., 2002). 
Platelets APP ratio may be altered early in AD and can be used to detect the conversion of 
mild cognitive impairment to AD  (Borroni et al., 2003; Borroni et al., 2006) and also to monitor 
treatment responses  (Borroni et al., 2001; Liu et al.,2005). However this method is not 
quantitative and there are important differences in reported data between different studies; 
this is likely due to differences in multiple steps of sample management and processing. 
www.intechopen.com
 
In Search of Therapeutic Solutions for Alzheimer’s Disease 
 
133 
2.1.7 Platelets tau 
Our group has recently demonstrated that platelets also contain tau protein. High molecular 
weight forms of tau that probably correspond to oligomeric protein can be resolved by 
electrophoresis and immunoblot with tau specific antibodies. The ratio of high molecular 
weight tau to normal weight tau in platelets is increased in AD patients so this kind of 
analysis may represent a novel biomarker for AD  (Neumann et al., 2011). 
2.2 Disease specific radiotracers: New avenues to pathology-specific imaging 
technologies  
The development of new NMR and PET imaging technologies has become a topic of major 
interest for both clinical and fundamental neuroscientists over the past few years, as it 
presents the unparalleled possibility of visualizing pathological processes in the brain 
parenchyma in a non-invasive and real time manner. Major progresses have been 
achieved in this field in the past decade mainly due to the use of functional NMR 
technologies and innovative PET tracers. However, although these current neuroimaging 
technologies provide precise information on structural and functional aspects of the brain, 
they have failed to provide information on the specific pathological processes and 
structural alterations occurred in different neurodegenerative diseases, including 
Alzheimer. Therefore, the development of new pathology-specific imaging technologies is 
still an urgent need. This would allow us to make a more accurate diagnose of brain 
disorders and also to efficiently monitor a number of experimental therapies currently 
under investigation.  
Regarding AD-specific PET tomography, researchers have focused their attention mainly on 
obtaining maps of the proposed hallmark lesions of this disease, i.e., the senile plaques (SP) 
and the neurofibrillary tangles (NFT´s) formed by hyperphosphorylated tau. After the 
publication of Klunk et al. (Klunk et al., 2004) reporting the potential application of 
Pittsburgh Compound-B as a specific radiotracer for the amyloid deposits in the human 
brain, a new era in the development of in vivo AD neuroimaging seems to have started. 
Almost at the same time Verhoeff et al. (Verhoeff et al., 2004) published a similar study with 
another PET radiotracer. None of these studies probed to be applicable for diagnosis of early 
stages of AD. However they helped us to understand the clinical significance of visualizing 
cerebral amyloid burden in AD diagnosis. Not long after reports on amyloid-specific PET 
tracers were published, several groups including ours pointed out the relevance of 
addressing this challenge from a seemingly more relevant a -and perhaps more efficient- 
perspective, which is visualizing aggregated forms of tau protein. (Rojo et al., 2007a, 2007b). 
Recently we reported the potential of benzimidazoles derivatives as pathology-specific PET 
tracers (Rojo et al., 2010). This work led us to discover that FDA-approved drugs, such as 
Lansoprazole and Astemizole (Rojo et al., 2010), were promising candidates for AD-specific 
radiotracers (Figures 2 and 3).  
The existence of a pathology-specific neuroimaging technology of AD would also allow a 
rational evaluation of the biological effects of a number of experimental pharmacological 
therapies available presently, as well as other promising tools to treat AD patients, and 
methods for clinical trial of anti-tau therapeutic approaches (Rojo et al., 2011). 
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Molecular structure of these ligands varies from large proteins and peptides such as the A 
peptide and radio-active monoclonal antibodies to small molecules derived from Congo red, 
Chrisamina-G, tioflavine-T, and acridine orange (Figure 2). Recent studies have 
demonstrated that is possible to obtain images of plaques and NFTs in vivo whether 
separately or simultaneously. So far, the most successful molecules have been those with a 
relatively low molecular weight (Figure 2) (Mathis et al., 2005). It has been shown that some 
benzimidazole and quinoline derivatives tag aggregated forms of tau in vitro and in the 
context of human brain (Mathis et al., 2005; Okamura et al., 2004; Okamura et al., 2005; Rojo 
et al., 2007a). This could serve as the milestone for developing neuroimaging technologies to 
visualize NFTs in the brain of AD patients and those affected with mild cognitive 
impairments (MCI). We believe that in the future, significant progress will be achieved in 
this area due to the recent discovery of different benzimidazoles and benzothiazoles with 
high affinity for brain aggregates of tau protein (Rojo et al., 2007b). Another important step 
in this area is the search of FDA-approved drug with similar structural features to those of 
Thioflavine T and other benzothiazole compounds. This implies the possibility of skipping 
expensive, cumbersome and time-consuming safety studies in humans for their approval in 









Fig. 2. Benzimidazole and benzothiazole derivatives proposed as potential biomarkers for 
PET imaging in AD. Several small molecules have been proposed as PET tracers for both 
amyloid and tau aggregates. In this figure ThS shows the proposed structures for 
Thioflavine S (ThS); Thioflavine T (ThT); Pittsburgh compound (PIB), and other amyloid 
specific radiotracers such as 6-ME-BTA 2 and 6ME-BTA-0. Also here the figure shows the 
NFTs-specific proposed PET tracers Astemizole, Lansoprazole, BF-126, BF 170, and BF-158.  
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Fig. 3. Neuropathological staining of brain sections from the entorhinal cortex of AD 
patients. Senile plaques (red arrowheads) and NTFs (yellow arrowheads) can be clearly 
tagged by Thioflavine-S  (B, C). Lansoprazole (A,D) tagged NFTs and neurite-like structures 
in the core of senile plaques.  
3. Novel approaches toward prevention and treatment of Alzheimer´s  
Disease (AD) 
AD is the most common type of dementia characterized by the formation of two main 
protein aggregates in the brain: senile plaques (SP) consisting of the amyloid-ǃ peptide and 
neurofibrillary tangles (NFT´s), consisting of the microtubule-associated protein tau. Tau 
accumulates in a hyperphosphorylated state forming intracellular deposits named to as 
paired helical filaments which generate the NFT´s (Maccioni et al., 2010). Formally approved 
during the past two decades, pharmacological treatments for AD are mainly based on 
restoring the levels of acetylcholine transmission in the brain being essentially symptomatic 
therapies. The anticholinesterase (anti-ChE) agents currently used such as rivastigmine, 
donepezil and galantamine failed in providing a substantial improvement in the mental 
health condition of AD patients (Aizenstein, 2008). Cholinesterase inhibitors appear to 
increase phosphorylated tau in AD (Chalmers et al., 2009). Anti-ChE drugs are being used 
for symptomatic treatment of mild to moderate AD. Tacrine was the first anti-ChE which 
showed positive clinical results, however, it is not in use any more due to severe 
hepatotoxicity. Through the progress of AD, brain cholinergic neurotransmission becomes 
significantly diminished, thus limiting clinical efficacy of the above mentioned anti-ChE 
agents. A new drug is being used CerebrolysineTM, based on a combination of peptides and 
administered intravenously, has shown discrete results. On the other hand the drug 
memantine, which modulates NMDA-related pathways in brain, has shown moderate 
results in cases of mild to advanced stages of AD. Moreover, nonsteroidal anti-inflammatory 
drugs (NSAIDs) appears as promising treatments according to epidemiological studies are 
able to reduce the risk of developing AD. A 2006 pilot study showed small but significant 
improvements in various cognitive rating scales in patients with AD after treatment with 
etanercept (Tobinick et al. 2008a,b; Navarrete et al., 2011). A further study, administering to 
a single AD patient via perispinal infusion, showed rapid and significant improvement of 
Alzheimer's symptoms. Nowadays over 300 compounds are being tested for AD at different 
stages of development, 175 of them are being evaluated at the level of clinical trials. 
However, the finalized studies have shown only negative results, creating great concern 
among the medical community who is still expecting an efficacious therapy for AD. 
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Another compound is huperzine A, an acetylcholinesterase inhibitor that occurs naturally in 
a species of moss that has been used in China for centuries for the treatment of blood 
disorders (Wang et al., 2011). The herb has been used to treat AD in China since the late 
1990’s and is sold in the US as a dietary supplement to help maintain memory (Rafii et al., 
2011). The first synthetic approach to produce huperzine A, was recently published aiming 
to replace the only natural source of huperzine A, the plant Huperzia serrata, which produces 
small amounts of huperzine A. Another drug, memantine directed to NMDA receptors, 
shows only moderate actions in advanced cases of the disease (Raina et al., 2008). On the 
other hand, recent anti-amyloid strategies, have failed in their efficacy or safety on their last 
development phases (Holmes et al., 2008). Statins appear to reduce the burden of NFTs, but 
clinical studies are not conclusive (Rojo et al., 2006; Boimel et al., 2009). In the whole context, 
tau based therapies represent a potential therapeutic target, specifically those that that 
diminish its aggregation, or alter its hyperphosphorylation (Alvarez et al., 2001). To those 
agents, several anti-tau miscellaneous strategies such as normal microtubule-stabilizing 
agents can be added to the new search for anti-AD drugs (Maccioni, 2011; Navarrete et al., 
2011). Thus, a combination of molecules such as anti-tau agents will be determinant for a 
substantial control of AD in the future. 
3.1 Searching for innovative tau aggregation inhibitors 
Physiologically tau stabilizes the microtubule structure, but in the neurons of patients with 
AD the microtubule system is believed to be disrupted, with the concomitant axonal 
transport deficits and degeneration (Farias et al., 2011). Several lines of evidence have shown 
that tau aggregation is the main event involved in the neurodegenerative process, due to the 
conversion of either soluble tau or oligomers into insoluble filaments. This process correlates 
with the clinical progression of AD and cognitive impairment (Maccioni and Perry, 2009). 
The identification of mutations in the tau gene in hereditary frontotemporal dementia 
revealed that tau dysfunction is central to neurodegeneration (Nakashima et al., 2005). Thus, 
improvement in the cognition of a transgenic model displaying both NFT´s and SP depends 
on blockage of tau filaments formation (Zhang et al., 2005). Cellular models where tau is 
overexpressed evidence the cytotoxicity of formed intracellular aggregates. In the search of 
new molecules for the treatment of AD, many drugs focused on Aǃ aggregation have failed 
in stopping the progression of the disease (Navarrete et al., 2011). The immunization against 
Aǃ was effective in reducing amyloid plaque load, but it had little effect on improving 
cognitive functions. A recent study shows the failure of a phase III clinical trial with a Ǆ-
secretase inhibitor (Carlson et al., 2011; Lleo and Saura, 2011). Therefore it seems timely to 
consider alternative drug discovery strategies for AD based on approaches directed at 
reducing misfolded tau and compensating for the loss of normal tau function.  
3.2 Tau hypothesis in the context of the AD clinic 
Nowadays AD etiopathogenesis is not yet established, despite different and numerous 
hypotheses (Maccioni and Perry, 2009). Nevertheless, there is agreement about its early 
onset, as a result of the convergence of a set of genetic and/ or environmental factors, which 
vary on time among patients and increase along with age (Glatz et al., 2006; Maccioni et al., 
2010). At different stages of the process, a cascade of pathological events is triggered, where 
factors such as Aǃ oligomers, iron overload or oxygen free radicals modify microglial cells 
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thus inducing anomalous signaling to neuronal cells (Fernandez et al., 2008; Maccioni et al., 
2009; Morales et al., 2010). These events finally result in alterations of cellular signposting and 
biochemical abnormalities that lead to cellular dysfunction, the lack of neurotransmission, 
cellular death and clinical expression of dementia.  
For years, the dominant hypothesis was that of the amyloid cascade, which sets the amyloid 
precursor protein (APP) metabolism dysfunction on the central nervous system, as the 
responsible agent for extraneuronal formation of SP (Hardy & Selkoe, 2002; Hardy, 2009). 
The major problem of this postulate is that a significant number of cognitively healthy 
elderly people, also exhibit abundant amyloid plaques, without a cognitive function 
impairment. Besides, diverse clinical assays carried out with different antiamyloid 
molecules, despite consistent effects on preclinical stages, have not shown cognitive and/or 
functional benefits in treated patients at advance stages of AD (Aizenstein et al., 2008; Panza 
et al., 2011). In this context, as the amyloid cascade hypothesis does not allow to explain the 
integrity of AD pathogenesis, the interest on tau hypothesis and neurofibrillary tangles, that 
sets tau protein abnormal phosphorylation as the possible responsible for these tangles 
formation, and the consequent neuronal death, has increased (Navarrete et al., 2011). On the 
other hand, recent data suggest an eventual connection between APP and tau protein, even 
though they have been treated as different contexts to physiopathologically explain AD 
(Alvarez et al., 2001; Otth et al., 2003; Czapski et al., 2011; Fuentes and Catalan, 2011). 
Studies in APP mice crossed to mutant tau mice, injection of Aǃ into the brain of these tau 
mutant mice and studies on neuronal cells, support the notion that Aǃ aggregates can drive 
neurofibrillary pathology (Otth et al., 2003; Hernandez et al., 2009; Kocherhans et al., 2010). 
Such investigations bear out the notion that although AD may be considered a primary Aǃ 
amyloidoses and a secondary tauopathy, tau pathology is the major factor that contributes 
to neurodegeneration (Maccioni et al., 2010).  
Moreover, FDA approved drugs over last decades are seemingly drugs which only reinforce 
cholinergic neurotransmission, as donepezil, galantamine and rivastigmine, or that 
moderates glutamate/NMDA receptor memantine are approved. After several years of 
clinical experience on drugs use, it can be concluded that AD treatment with cholinesterase 
inhibitors and memantine, is essentially symptomatic (Raina et al., 2008). Even though it 
may result in a moderate improvement, lacks of a real clinical output relative to cognition 
measurements and global evaluation of dementia. Recent in vitro and in vivo data suggest 
that cholinergic drugs may even have negative impact on e amiloyd-ǃ-peptide and tau 
behavior. According to recent studies, patients treated with ChEIs had accumulated 
significantly more phospho-tau in their cerebral cortex compared to untreated patients. This 
data suggests the possibility that increased tau phosphorylation may influence long-term 
clinical responsiveness to ChEIs (Chalmers et al., 2009; Fuentes and Catalan, 2011).  
Efforts to develop drugs more focused on AD underlying pathology, have considered 
different agents, called disease modifiers, and linked to diverse etiopathogenic hypotheses. 
Antiamyloid strategies, such as active or passive immunization, or secretase inhibitors, have 
been predominant, nevertheless they have failed on the efficacy or security on their last 
development phases (Lleo and Saura, 2011). Actually, molecules that could restrict tau 
aggregates and the consequent formation of neurofibrillary tangles, have already begun to 
be explored on clinical trials, having the consideration that the last mentioned lesions, are 
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the responsible for most of the AD cognitive impairments. However, the only anti-tau 
therapies that have reached the human clinical trial stage are lithium, methylene blue and 
NAP (Nakashima et al., 2005; Medina et al., 2011; Navarrete et al., 2011). 
3.3 Anti-tau miscellaneous strategies 
A variety of intracellular proteins have been implicated in regulating both tau aggregation 
and folding, or potentially mediate clearance of the misfolded and aggregated tau protein. 
In this context, the ubiquitin ligase C-terminus of heat shock cognate70-interacting protein 
(CHIP) can polyubiquitinate tau and may play a crucial role in preventing accumulation of 
phospho-tau and NFTs (Staff et al., 2008). Studies suggest that modulation of CHIP and the 
ubiquitin preoteasome system could alter tau pathology. Finally, heat shock proteins have 
been suggested as possible modifiers of tau pathology. HSP90 inhibitors that induce a heat 
shock response reduce tau phosphorylation at certain sites and are currently being tested in 
humans as anti-cancer agents (Dickey, 2007, reviewed in Fuentes and Catalan, 2011). Thus, 
on the basis of information that sequestration of tau results in loss of the normal 
microtubule-stabilizing function, normal microtubule-stabilizing agents have been tested in 
several tau mouse models. Paclitaxel administered to the tau mouse model, in a micellar 
formulation increased microtubule stability and rendered these polymers less dynamics. 
After three-months of paclitaxel treatment, transgenic mice showed rise on fast axonal 
transport and of the microtubules bundles in neuronal cells (Zhang et al., 2005). Authors 
also showed motor function improvement in comparison to the not-treated mice. 
Considering that paclitaxel does not cross hematoencephalic barrier, its action would be 
mediated through retrograde transport to spinal motoneurons among other possible 
explanations.  
Moreover, there is another compound named to as NAP, a derivative octapeptide of a 
natural neurotrophic protein, which cross the blood brain barrier, and has shown to 
promote microtubules assembly (Matsuoka et al., 2008). Nasal administration for several 
months to elderly mice that had developed tau aggregations and Aǃ deposition, resulted in 
reduction on tau phosphorylation and Aǃ levels, with a cognitive function improvement 
(Matsuoka et al., 2008). A similar approach has also been employed in an animal model of 
tauopathy, anti-tau pathologically phosphorylated immunotherapy, where a diminished 
charge of NFT´s was observed, and the presence of serum antibodies, without evidence of 
clinical deficits or encephalitis.  
3.4 AD prevention: The emergence of natural products in the control of tau pathology 
The development of small-molecules that inhibit the aggregation of tau appears as a valid 
therapeutic target for treatment of AD and as a consequence of the failure on drugs directed 
against the amyloid and the cumulative evidence in favor of tau hypothesis, current 
therapeutic strategies are aimed at searching for compounds that can either inhibit the 
formation of pathological tau filaments or disaggregate them. This hypothesis has been 
favored by current findings on the compound methylthioninium chloride (known as 
methylene blue), a previously described inhibitor of tau aggregation. A recent study with 
this compound in phase II clinical trial shows an 81% reduction of cognitive decline with the 
use of the compound as compared to placebo (Wischik et al., 1996; Medina et al., 2011). 
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Compounds described for their anti-aggregating capacity in the formation of amyloid 
aggregates are the polyphenols. In this context, synthetic polyphenols have proved 
effectiveness in the inhibition of heparin-induced tau aggregation. Following this approach, 
the current therapeutic strategies are aimed to look for natural phytochemicals and 
polyphenolic extracts that can be able to either inhibit or disaggregate tau filament 
formation (Bastianetto et al., 2008; Kim et al., 2010; Cornejo et al., 2011). It has been 
suggested that naturally occurring phytochemicals have the potential to prevent AD based 
on their anti-amyloidogenic, anti-oxidative and anti-inflammatory properties. Despite this, 
there are few phytocomplexes emerging in order to prevent tau aggregation. Only a 
cinnamon extract and a grape seed polyphenolic extract have been described for this 
purpose (Peterson et al., 2009). Fulvic acid is one of the most interesting phytocomplex 
molecules (Goshal et al., 1990). This is a mixture of polyphenolic acid compounds resulting 
from the long-term microbial degradation of lignin, among other sources. It has several 
nutraceutical properties, and is one of the most interesting naturally-occurring 
phytochemicals for their extremely high antioxidant properties and apparent 
neuroprotective effect. For instance, the interaction of prion protein with fulvic acid and its 
inhibitory effect on the content of ǃ-sheet structure and the formation of protein aggregates 
has been described in detail. Only a few polyphenolic molecules have emerged to prevent 
tau aggregation, and natural drugs targeting against tau have not been approved yet 
(Peterson et al., 2009; Cornejo et al., 2011). Fulvic acid, a humic substance, has several 
nutraceutical properties with potential activity to protect cognitive impairment. In this work 
we provide evidence to show that aggregation process of tau protein, forming paired helical 
filaments (PHFs) in vitro, is inhibited by fulvic acid affecting the length of fibrils and their 
morphology (Cornejo et al., 2011; Carrasco et al., unpublished results). In addition, we 
investigated whether fulvic acid is capable of disassembling preformed PHFs. We showed 
by mean of analysis of aggregation, atomic force microscopy (AFM) and electron 
microscopy that the fulvic acid is an active compound against pre formed fibrils affecting 
the whole structure by diminishing length of PHFs and probably acting at the hydrophobic 
level, as we observed by mean of atomic force techniques. Thus, fulvic acid is likely to 
provide a new insight to develop potential treatments for AD based on natural products. 
These observations allowed us to conclude that fulvic acid inhibits heparin-induced tau 
aggregation in vitro. On the other hand, fulvic acid promotes the disassembling of tau 
preformed fibrils. Thus, fulvic acid could provide a new insight for developing treatments 
based on natural products for AD (Cornejo et al., 2011; Farias et al, unpublished 
observations).  
4. Conclusion  
A major hallmark of AD is the presence of NFT´s containing tau protein. The 
neuroimmunomodulation theory of AD together with the revitalized tau hypothesis on 
Alzheimer´s pathogenesis provided a fundamental paradigm to understand this disease. 
This is very important considering that the slow progress in therapeutic approaches has 
been the result of a lack of a solid paradigm on this devastating disease. In this context, 
beside the anticholinesterases, most researchers have focused on drugs that affect the 
production of ǃ-amyloid or disassembly of senile plaques, with very limited results. 
Therefore, tau became a major target for future therapeutic approaches. As tau clearly 
presents a potential therapeutic target in AD, there is a high rise on new drugs investigation 
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that would early interfere with the cascade that leads to tangles formation, and that might 
contribute to control neuronal degeneration and cognitive impairment. A critical step in the 
design of potential strategies to control AD is to find reliable biomarkers for its early 
diagnosis. Despite many efforts in this direction no markers to detect AD at the pre-
symptomatic level are available. After the acceptance of tau/amyloid biomarker in the CSF, 
research is directed to establish a non-invasive marker technology. Innovative studies point 
to an in vivo PET technology based on neuroimaging of NFT´s and tau filaments by using 
lansoprazole as a radiotracer, and blood biomarkers based on altered tau and amyloid 
variants in platelets.  
Considering the scenario in which new synthesized drugs and novel therapeutic approaches 
have failed in their clinical trials, new hopes come from the search of natural products and 
phytocomplexes. Polyphenols have been described for their anti-aggregating capacity in the 
formation of amyloid aggregates. Most recently, synthetic polyphenols have proved 
effectiveness in the inhibition of heparin-induced tau aggregation. Following this approach, 
the current therapeutic strategies are aimed at looking for natural phytochemicals and 
polyphenolic extracts able to either inhibit or disaggregate tau filament formation. In 
addition, it has been suggested that naturally occurring phytocomplexes have the potential 
to prevent AD based on their neuroprotective, anti-oxidative and anti-inflammatory 
properties. Despite this, there are few natural complexes emerging in order to prevent tau 
aggregation. These include cinnamon and grape extracts, the anti-oxidant resveratrol, and 
recently fulvic acid. The combination of vitamins essential for brain health such as folic acid, 
vitamins B6 and 12 with natural compounds such as natural extracts from plants, flavones, 
flavonoids and the natural product shilajit offer an interesting approach toward the therapy 
of Alzheimer´s disease.  
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